

EIP



Pregabalin litigation - why did the SPCs lapse?

Writing in the GRUR Newsletter ahead of the decision of the Supreme Court on the validity of a European patent owned by a subsidiary of Pfizer, covering the use of pregabalin in the treatment of pain, Darren Smyth looks at the various theories as to why the related SPCs were allowed to lapse.